Restoration of the Gut Microbiome After Cesarean Section

Last updated: September 18, 2024
Sponsor: Professor Klaus Bønnelykke
Overall Status: Active - Recruiting

Phase

1

Condition

N/A

Treatment

Microbiome restoration - FVT

Placebo

Vaginal birth, untreated control

Clinical Study ID

NCT06264219
H-24002284
  • Ages > 18
  • Female
  • Accepts Healthy Volunteers

Study Summary

This study aims to develop a therapy for restoring the gut microbiome in infants born via CS. The Study will conduct a randomized, placebo-controlled feasibility trial to assess the ability of microbiome restoration by FMT and FVT in infants born by cesarean section.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Gestational age < week 38+0 days

  • Proficient in spoken/written Danish

  • Single pregnancy (no twins or triplets)

  • Pre-pregnancy BMI between 18.5 and 35 kg/m2

  • No chronic intestinal, endocrine, cardiac, or kidney disorders

  • No known gestational complications (gestational diabetes, preeclampsia, gestationalhypothyroidism)

  • No regular use of prescription medication or any drugs that, in the research team'sopinion, may interfere with the study's results.

  • Willingness to abstain from giving the child products with probiotics (fermenteddairy like yogurt or A38 are allowed).

Exclusion

Exclusion Criteria:

Maternal:

  • Use of antibiotics within one month of stool donation

  • Acute gastroenteritis within one month of stool donation

  • Use of antibiotics within one month of birth

  • Time since last travel abroad relative to data of fecal donation according to therequirements for blood donations ("Regler for tappepauser" - blooddonor.dk)

  • Positive test results for pathogens during donor material screening.

  • Antibiotic treatment at birth (vaginal births only)

  • Spontaneous onset of labor or emergency cesarean section before scheduled cesareansection.

Infant:

  • Instances of major birth defects or intrauterine growth retardation (IUGR)

  • Infants requiring pediatric support at the time of transplant administration

Study Design

Total Participants: 80
Treatment Group(s): 4
Primary Treatment: Microbiome restoration - FVT
Phase: 1
Study Start date:
August 02, 2024
Estimated Completion Date:
November 30, 2026

Study Description

When a child is born vaginally, the passage through the birth canal provides the first and very important bacterial colonization. As the child ages, various environmental exposures, such as dietary changes and the presence of older siblings in the home, facilitate a natural maturation of the child's gut microbiome, providing a vast and continuous stimulation of the child's developing immune system. However, factors such as mode of delivery and intrapartum antibiotics can perturb this natural developmental process and cause long-term microbial derangements. The prevalence of cesarean section (CS) birth has increased globally in recent decades, and with it, antibiotic treatment to prevent perinatal infection. Similar patterns have occurred for the prevalence of chronic childhood disease, particularly asthma, with an estimated 300 million asthmatic cases worldwide.

The hypothesis is that early intervention with mother-to-infant FMT can restore a CS-perturbed microbiome to a normal microbial trajectory. Another hypothesis is that seeding the virome fraction (FVT) will cause the neonate's microbiome to resemble the mother's since the transferred phages are enriched and preserved in the intestinal mucus layer, thereby providing the recipient with selective antimicrobial protection while allowing species resembling the mother's own to establish during subsequent bacterial transmission.

Connect with a study center

  • Copsac, DBAC

    Gentofte, Copenhagen 2820
    Denmark

    Active - Recruiting

  • Rigshospitalet

    Copenhagen, 2100
    Denmark

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.